TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data
Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug. Earlier this month, TG Therapeutics reported positive early results for a new under-the-skin version of BRIUMVI in patients with myasthenia gravis. Prior to that, the company also released encouraging early data showing that the under-the-skin shot is well absorbed … Read more